NYSE: DBDDiebold Nixdorf Inc Stock
$41.79+1.19 (+2.93%)
Updated Apr 22, 2025
DBD Price
$41.79
Fair Value Price
N/A
Market Cap
$1.57B
52 Week Low
$30.37
52 Week High
$51.81
P/E
-94.98x
P/B
1.69x
P/S
0.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.75B
Earnings
-$16.50M
Gross Margin
24.5%
Operating Margin
5.41%
Profit Margin
-0.4%
Debt to Equity
2.8
Operating Cash Flow
$149M
Beta
1.06
Next Earnings
Apr 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DBD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important DBD news, forecast changes, insider trades & much more!
DBD News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DBD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DBD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DBD is good value based on its book value relative to its share price (1.69x), compared to the US Software - Application industry average (6.34x)
P/B vs Industry Valuation
DBD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DBD due diligence checks available for Premium users.
Valuation
DBD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-94.98x
Industry
111.4x
Market
28.14x
DBD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.69x
Industry
6.34x
DBD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DBD's financial health
Profit margin
Revenue
$988.9M
Net Income
$5.6M
Profit Margin
0.6%
DBD's Earnings (EBIT) of $203.10M... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.5B
Liabilities
$2.6B
Debt to equity
2.8
DBD's short-term assets ($1.67B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DBD's short-term assets ($1.67B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DBD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$196.2M
Investing
-$17.3M
Financing
-$192.0M
DBD's operating cash flow ($149.20M)... subscribe to Premium to read more.
Debt Coverage Financials
DBD vs App Stocks
Diebold Nixdorf Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.